Study Description

PRIMARY OBJECTIVES:

I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by progression-free survival (PFS) in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess the efficacy of the combination of cediranib and olaparib, and cediranib monotherapy, as measured by overall survival (OS) and PFS, as compared to physician's choice standard of care chemotherapy in women with recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

SECONDARY OBJECTIVES:

I. To assess the efficacy of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by objective response rate (ORR: partial or complete response) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess safety endpoints, as measured by frequency and severity of adverse events by Common Terminology Criteria for Adverse Events (CTCAE). (Phase II and Phase III) III. To assess the efficacy of the combination of cediranib and olaparib, and cediranib monotherapy, as measured by ORR as compared to physician's choice standard of care chemotherapy in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

OBJECTIVES WITH INTEGRATED BIOMARKERS:

I. To assess correlation of homologous recombination deficiency (HRD) status, as assessed via BROCA-HR assay with response, as measured by PFS and ORR. (Phase II) II. To evaluate the prognostic and predictive role of circulating endothelial cells (CEC) on comparative effectiveness of targeted therapies and reference chemotherapy. (Phase II) III. To evaluate quality of life data compliance, as measured by the 9-item Disease Related Symptoms (DRS-9) subscale of the National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) Ovarian Symptom Index (NFOSI) for utilization and analysis in the Phase III study. (Phase II) IV. To assess correlation of HRD status, as assessed via BROCA-HR assay with response, as measured by OS, PFS and ORR. (Phase III) V. To evaluate the prognostic and predictive role of circulating endothelial cells (CEC) on comparative effectiveness of targeted therapies and reference chemotherapy. (Phase III) VI. To assess the effect on disease-related symptoms (DRS) as measured by the 9-item DRS-P subscale of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), of single agent cediranib and cediranib/olaparib combination, compared to standard chemotherapy, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

EXPLORATORY OBJECTIVES:

I. To assess exploratory biomarkers of potential HRD, including genomic scarring, BRCA1 methylation, BRCA1 protein expression, and mutations in NHEJ, and other genes that might modify HRD. (Phase II and Phase III) II. To evaluate the prognostic and predictive role of angiogenic biomarkers, as assessed by the Duke plasma angiome. (Phase II and Phase III) III. To assess the effect on secondary measures of quality of life, as assessed by the treatment side effects (TSE) and function/well-being (F/WB) subscales of the NFOSI-18, sensory neuropathy as measured by the FACT/GOG-Ntx-4, and health utility as measured by the EQ-5D, of single agent cediranib and cediranib/olaparib combination, compared to standard chemotherapy, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)

OUTLINE:

PHASE II: Patients are randomized to 1 of 4 treatment arms.

ARM I (REFERENCE REGIMEN): Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel intravenously (IV) over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo computed tomography (CT) and magnetic resonance imaging (MRI) throughout the study. (12/05/2016)

ARM II (CEDIRANIB MALEATE AND OLAPARIB): Patients receive cediranib maleate orally (PO) once daily (QD) and olaparib PO twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.

ARM III (CEDIRANIB): Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.

ARM IV (OLAPARIB): Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).

PHASE III: Patients are randomized to 1 of 3 treatment arms.

ARM I (REFERENCE REGIMEN): Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)

ARM II (CEDIRANIB AND OLAPARIB): Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.

ARM III (SINGLE AGENT): Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for up to 3 years.

Condition or Disease

Intervention/Treatment

Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Fallopian Tube Undifferentiated Carcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Carcinoma Ovarian Undifferentiated Carcinoma Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma

Drug: Cediranib Drug: Cediranib Maleate Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Drug: Olaparib Drug: Paclitaxel Drug: Pegylated Liposomal Doxorubicin Hydrochloride Other: Questionnaire Administration Drug: Topotecan Drug: Topotecan Hydrochloride

Study Design

Study Type	Interventional
Actual Enrollment	587 participants
Design Allocation	Randomized
Interventional Model	Parallel Assignment
Masking	None (Open Label)
Primary Purpose	Treatment
Official Title	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Study Start Date	May 3, 2016
Actual Primary Completion Date	June 12, 2023
Anticipated Study Completion Date	July 12, 2025

Groups and Cohorts

Group/ Cohort	Intervention/ Treatment
Phase II Arm I (reference regimen) Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)	Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Drug: Paclitaxel Drug: Pegylated Liposomal Doxorubicin Hydrochloride Other: Questionnaire Administration Drug: Topotecan Drug: Topotecan Hydrochloride
Phase II Arm II (cediranib maleate, olaparib) Patients receive cediranib maleate PO QD and olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.	Drug: Cediranib Given PO Drug: Cediranib Maleate Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Drug: Olaparib Other: Questionnaire Administration
Phase II Arm III (cediranib maleate) Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.	Drug: Cediranib Given PO Drug: Cediranib Maleate Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Other: Questionnaire Administration
Phase II Arm IV (olaparib) Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).	Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Drug: Olaparib Other: Questionnaire Administration
Phase III Arm I (reference regimen) Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)	Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Drug: Paclitaxel Drug: Pegylated Liposomal Doxorubicin Hydrochloride Other: Questionnaire Administration Drug: Topotecan Drug: Topotecan Hydrochloride
Phase III Arm II (cediranib maleate, olaparib) Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.	Drug: Cediranib Given PO Drug: Cediranib Maleate Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Drug: Olaparib Other: Questionnaire Administration
Phase III Arm III (single-agent cediranib maleate) Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.	Drug: Cediranib Given PO Drug: Cediranib Maleate Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Other: Questionnaire Administration

Outcome Measures

Primary Outcome Measures

1. Progression-free survival (PFS) (Phase II and Phase III) [Time from study enrollment to the onset of progression as determined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST) criteria, or death due to any cause, whichever occurs first, assessed up to 5 years]
   Progression-free survival will be assessed. The primary analysis of PFS will be assessed using a proportional hazards model with patients analyzed according to the arm to which they were randomized, regardless of whether treatment is received.
2. Overall survival (OS) (Phase III) [Time from study enrollment to death due to any cause, assessed up to 5 years]
   Overall survival will be evaluated. To allow for better understanding of time to subsequent therapy and OS, patients on experimental study drug(s) or standard chemotherapy arm will be followed after progression, with data capture to include the date of initiation of the subsequent therapy, detailed information on the type of subsequent therapy received, and time to progression on the subsequent therapy.

Secondary Outcome Measures

1. Objective response rate (partial or complete response) (Phase II and Phase III) [Up to 5 years]
   Objective response rate will be defined by RECIST 1.1.
2. Incidence of adverse events (Phase II and Phase III) [Up to 5 years]
   Frequency and severity of adverse events measured by Common Terminology Criteria for Adverse Events version 4.0

Eligibility Criteria

Ages Eligible for Study	18 Years and Older (Adult, Older Adult)
Sexes Eligible for Study	Female
Accepts Healthy Volunteers	No
Inclusion Criteria	Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of either serous or endometrioid cancer based on local histopathological findings; both endometrioid and serous histology should be high-grade for eligibility of non-mutation carriers; patients with clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory Note: Due to the long acceptance of BRCA testing through Myriad, Myriad testing will be accepted; if testing for BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germ line deleterious BRCA 1 or BRCA 2 mutation or BRCA rearrangement is required (12/05/2016); a copy of Myriad or other BRCA mutational analysis (positive or variants of unknown significance [VUS] or negative) reports will be requested but not required for study enrollment Patients should have recurrent platinum-resistant or- refractory disease - defined as disease that has progressed by imaging while receiving platinum or had recurrence within 6 months of the last receipt of platinum-based chemotherapy; rising CA125 only is not considered as platinum-resistant or refractory disease (12/05/2016) Phase II study: measurable disease by RECIST 1.1 criteria; if archival tumor sample is not available tumor sample from fresh biopsy is acceptable (12/05/2016) Phase III study: evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a cancer antigen [CA]125 >= 2 x upper limit of normal [ULN]) No more than 3 prior treatment regimens (including primary therapy; no more than 1 prior non-platinum based therapy in the platinum-resistant/-refractory setting); hormonal therapies used as single agents (i.e. tamoxifen, aromatase inhibitors) will not count towards this line limit (12/05/2016) Patients may not have had a prior anti-angiogenic agent in the recurrent setting; prior use of bevacizumab in the upfront or upfront maintenance setting is allowed Patients may not have previously received a PARP-inhibitor Patient must have provided study specific informed consent prior to study entry Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2 Absolute neutrophil count >= 1,500/mcL (12/05/2016) Platelets >= 100,000/mcL (12/05/2016) Hemoglobin >= 10 g/dL (12/05/2016) Total bilirubin within =< 1.5 times the upper limit of normal (ULN) institutional limits (12/05/2016) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN; if intrahepatic liver metastases are present, AST and ALT must be =< 5 times institutional ULN (12/05/2016) Creatinine =< 1.5 x the institutional ULN (12/05/2016) Urine protein: creatinine ratio urine protein creatinine (UPC) of =< 1 OR less than or equal to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart; UPC is the preferred test; patients with 2+ proteinuria on dipstick must also have a 24-hour urine collection demonstrating protein of =< 500 mg over 24 hours (12/05/2016) Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the study chair. Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on maximum of three antihypertensive medications; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol; patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to cediranib alone and the combination of olaparib and cediranib arms (12/05/2016) Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid-stimulating hormone (TSH) within normal limits (12/05/2016) Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib Age >= 18 years Cediranib has been shown to terminate fetal development in the rat, as expected for a process dependent on VEGF signaling; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 weeks after cediranib discontinuation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately Olaparib adversely affects embryofetal survival and development in the rat; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 3 months after the last dose of olaparib; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Exclusion Criteria	Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions (12/05/2016) Any other investigational agents within the past 4 weeks Prior treatment affecting the VEGF/VEGFR pathway or the angiopoietin pathway in the recurrent setting, including but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, pazopanib, cediranib, nintedanib, and trebananib; bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowed Prior use of PARP-inhibitors CA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable or otherwise evaluable disease Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugs History of intra-abdominal abscess within the past 3 months History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least 6 months, and patient is deemed to be at low risk of recurrent fistula (12/05/2016) Dependency on IV hydration or total parenteral nutrition (TPN) Any concomitant or prior invasive malignancies with the following curatively treated exceptions: Treated limited stage basal cell or squamous cell carcinoma of the skin Carcinoma in situ of the breast or cervix Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions (12/05/2016) Prior cancer treated with a curative intent with no evidence of recurrent disease 5 years following diagnosis and judged by the investigator to be at low risk of recurrence Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events; patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study drug Patients with any of the following: History of myocardial infarction within six months Unstable angina Resting electrocardiogram (ECG) with clinically significant abnormal findings New York Heart Association functional classification of III or IV If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines Patients with the following risk factors should have a baseline cardiac function assessment: Prior treatment with anthracyclines Prior treatment with trastuzumab Prior central thoracic radiation therapy (RT), including RT to the heart History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study) Prior history of impaired cardiac function History of stroke or transient ischemic attack within six months Clinical significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection) Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT) Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements (12/05/2016) Known human immunodeficiency virus (HIV)-positive individuals are ineligible because of the potential for pharmacokinetic interactions with cediranib or olaparib; in addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible Strong inhibitors and inducers of UGT/PgP should be used with caution (12/05/2016) Pregnant women are excluded from this study because cediranib and olaparib are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with cediranib and olaparib, breastfeeding should be discontinued if the mother is treated with cediranib or olaparib; these potential risks may also apply to other agents used in this study

Contacts and Locations

Sponsors and Collaborators	National Cancer Institute (NCI), Canadian Cancer Trials Group, NRG Oncology
	Canadian Cancer Trials Group, NRG Oncology
Locations	University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States, 35233 Alaska Women's Cancer Care | Anchorage, Alaska, United States, 99508 Providence Alaska Medical Center | Anchorage, Alaska, United States, 99508 University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States, 72205 Sutter Auburn Faith Hospital | Auburn, California, United States, 95602 Alta Bates Summit Medical Center-Herrick Campus | Berkeley, California, United States, 94704 Mercy San Juan Medical Center | Carmichael, California, United States, 95608 Mercy Cancer Center - Elk Grove | Elk Grove, California, United States, 95758 Marin Cancer Care Inc | Greenbrae, California, United States, 94904 UC San Diego Moores Cancer Center | La Jolla, California, United States, 92093 Palo Alto Medical Foundation-Camino Division | Mountain View, California, United States, 94040 Palo Alto Medical Foundation-Gynecologic Oncology | Mountain View, California, United States, 94040 Kaiser Permanente-Oakland | Oakland, California, United States, 94611 Palo Alto Medical Foundation Health Care | Palo Alto, California, United States, 94301 Mercy Cancer Center - Rocklin | Rocklin, California, United States, 95765 Sutter Roseville Medical Center | Roseville, California, United States, 95661 Kaiser Permanente Downtown Commons | Sacramento, California, United States, 95814 Mercy Cancer Center - Sacramento | Sacramento, California, United States, 95816 Sutter Medical Center Sacramento | Sacramento, California, United States, 95816 University of California Davis Comprehensive Cancer Center | Sacramento, California, United States, 95817 Kaiser Permanente - Sacramento | Sacramento, California, United States, 95825 California Pacific Medical Center-Pacific Campus | San Francisco, California, United States, 94115 Kaiser Permanente-San Francisco | San Francisco, California, United States, 94115 UCSF Medical Center-Mission Bay | San Francisco, California, United States, 94158 Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo, California, United States, 93401 Kaiser Permanente Medical Center - Santa Clara | Santa Clara, California, United States, 95051 Palo Alto Medical Foundation-Santa Cruz | Santa Cruz, California, United States, 95065 Sutter Pacific Medical Foundation | Santa Rosa, California, United States, 95403 Palo Alto Medical Foundation-Sunnyvale | Sunnyvale, California, United States, 94086 Kaiser Permanente-Vallejo | Vallejo, California, United States, 94589 Kaiser Permanente-Walnut Creek | Walnut Creek, California, United States, 94596 Woodland Memorial Hospital | Woodland, California, United States, 95695 UCHealth University of Colorado Hospital | Aurora, Colorado, United States, 80045 Penrose-Saint Francis Healthcare | Colorado Springs, Colorado, United States, 80907 UCHealth Memorial Hospital Central | Colorado Springs, Colorado, United States, 80909 Kaiser Permanente-Franklin | Denver, Colorado, United States, 80205 Rocky Mountain Cancer Centers-Rose | Denver, Colorado, United States, 80220 Poudre Valley Hospital | Fort Collins, Colorado, United States, 80524 UCHealth Highlands Ranch Hospital | Highlands Ranch, Colorado, United States, 80129 Kaiser Permanente-Rock Creek | Lafayette, Colorado, United States, 80026 Kaiser Permanente-Lone Tree | Lone Tree, Colorado, United States, 80124 Danbury Hospital | Danbury, Connecticut, United States, 06810 Smilow Cancer Hospital Care Center-Fairfield | Fairfield, Connecticut, United States, 06824 Hartford Hospital | Hartford, Connecticut, United States, 06102 Smilow Cancer Hospital Care Center at Saint Francis | Hartford, Connecticut, United States, 06105 Middlesex Hospital | Middletown, Connecticut, United States, 06457 The Hospital of Central Connecticut | New Britain, Connecticut, United States, 06050 Yale University | New Haven, Connecticut, United States, 06520 Norwalk Hospital | Norwalk, Connecticut, United States, 06856 Smilow Cancer Hospital Care Center-Trumbull | Trumbull, Connecticut, United States, 06611 Helen F Graham Cancer Center | Newark, Delaware, United States, 19713 Medical Oncology Hematology Consultants PA | Newark, Delaware, United States, 19713 Christiana Care Health System-Christiana Hospital | Newark, Delaware, United States, 19718 Sibley Memorial Hospital | Washington, District of Columbia, United States, 20016 University of Florida Health Science Center - Gainesville | Gainesville, Florida, United States, 32610 Mount Sinai Medical Center | Miami Beach, Florida, United States, 33140 Orlando Health Cancer Institute | Orlando, Florida, United States, 32806 Sarasota Memorial Hospital | Sarasota, Florida, United States, 34239 Emory University Hospital Midtown | Atlanta, Georgia, United States, 30308 Piedmont Hospital | Atlanta, Georgia, United States, 30309 Emory University Hospital/Winship Cancer Institute | Atlanta, Georgia, United States, 30322 Northside Hospital | Atlanta, Georgia, United States, 30342 Augusta University Medical Center | Augusta, Georgia, United States, 30912 WellStar Cobb Hospital | Austell, Georgia, United States, 30106 WellStar Health System Inc | Marietta, Georgia, United States, 30060 Wellstar Kennestone Hospital | Marietta, Georgia, United States, 30060 WellStar North Fulton Hospital | Roswell, Georgia, United States, 30076 Memorial Health University Medical Center | Savannah, Georgia, United States, 31404 Lewis Cancer and Research Pavilion at Saint Joseph's/Candler | Savannah, Georgia, United States, 31405 WellStar Vinings Health Park | Smyrna, Georgia, United States, 30080 Queen's Medical Center | Honolulu, Hawaii, United States, 96813 Kapiolani Medical Center for Women and Children | Honolulu, Hawaii, United States, 96826 Saint Alphonsus Cancer Care Center-Boise | Boise, Idaho, United States, 83706 Saint Luke's Cancer Institute - Boise | Boise, Idaho, United States, 83712 Saint Luke's Cancer Institute - Fruitland | Fruitland, Idaho, United States, 83619 Saint Luke's Cancer Institute - Meridian | Meridian, Idaho, United States, 83642 Saint Luke's Cancer Institute - Nampa | Nampa, Idaho, United States, 83686 Rush - Copley Medical Center | Aurora, Illinois, United States, 60504 Illinois CancerCare-Bloomington | Bloomington, Illinois, United States, 61704 Illinois CancerCare-Canton | Canton, Illinois, United States, 61520 Illinois CancerCare-Carthage | Carthage, Illinois, United States, 62321 Centralia Oncology Clinic | Centralia, Illinois, United States, 62801 Northwestern University | Chicago, Illinois, United States, 60611 John H Stroger Jr Hospital of Cook County | Chicago, Illinois, United States, 60612 Rush University Medical Center | Chicago, Illinois, United States, 60612 UChicago Medicine Comprehensive Cancer Center - Saint Joseph Hospital | Chicago, Illinois, United States, 60657 Cancer Care Specialists of Illinois - Decatur | Decatur, Illinois, United States, 62526 Decatur Memorial Hospital | Decatur, Illinois, United States, 62526 Crossroads Cancer Center | Effingham, Illinois, United States, 62401 Illinois CancerCare-Eureka | Eureka, Illinois, United States, 61530 NorthShore University HealthSystem-Evanston Hospital | Evanston, Illinois, United States, 60201 Illinois CancerCare-Galesburg | Galesburg, Illinois, United States, 61401 Northwestern Medicine Cancer Center Delnor | Geneva, Illinois, United States, 60134 NorthShore University HealthSystem-Glenbrook Hospital | Glenview, Illinois, United States, 60026 NorthShore University HealthSystem-Highland Park Hospital | Highland Park, Illinois, United States, 60035 Sudarshan K Sharma MD Limited-Gynecologic Oncology | Hinsdale, Illinois, United States, 60521 Illinois CancerCare-Kewanee Clinic | Kewanee, Illinois, United States, 61443 Illinois CancerCare-Macomb | Macomb, Illinois, United States, 61455 Cancer Care Center of O'Fallon | O'Fallon, Illinois, United States, 62269 Illinois CancerCare-Ottawa Clinic | Ottawa, Illinois, United States, 61350 Illinois CancerCare-Pekin | Pekin, Illinois, United States, 61554 Illinois CancerCare-Peoria | Peoria, Illinois, United States, 61615 Illinois CancerCare-Peru | Peru, Illinois, United States, 61354 Illinois CancerCare-Princeton | Princeton, Illinois, United States, 61356 Springfield Clinic | Springfield, Illinois, United States, 62702 Memorial Medical Center | Springfield, Illinois, United States, 62781 Northwestern Medicine Cancer Center Warrenville | Warrenville, Illinois, United States, 60555 Midwestern Regional Medical Center | Zion, Illinois, United States, 60099 Parkview Regional Medical Center | Fort Wayne, Indiana, United States, 46845 Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis, Indiana, United States, 46202 Ascension Saint Vincent Indianapolis Hospital | Indianapolis, Indiana, United States, 46260 Reid Health | Richmond, Indiana, United States, 47374 Memorial Hospital of South Bend | South Bend, Indiana, United States, 46601 Mercy Cancer Center-West Lakes | Clive, Iowa, United States, 50325 Mission Cancer and Blood - West Des Moines | Clive, Iowa, United States, 50325 Iowa Methodist Medical Center | Des Moines, Iowa, United States, 50309 Mission Cancer and Blood - Des Moines | Des Moines, Iowa, United States, 50309 Mercy Medical Center - Des Moines | Des Moines, Iowa, United States, 50314 Mission Cancer and Blood - Laurel | Des Moines, Iowa, United States, 50314 University of Iowa/Holden Comprehensive Cancer Center | Iowa City, Iowa, United States, 52242 Siouxland Regional Cancer Center | Sioux City, Iowa, United States, 51101 Mercy Medical Center-West Lakes | West Des Moines, Iowa, United States, 50266 Associates In Womens Health | Wichita, Kansas, United States, 67208 Ascension Via Christi Hospitals Wichita | Wichita, Kansas, United States, 67214 Saint Elizabeth Healthcare Edgewood | Edgewood, Kentucky, United States, 41017 University of Kentucky/Markey Cancer Center | Lexington, Kentucky, United States, 40536 Hematology/Oncology Clinic PLLC | Baton Rouge, Louisiana, United States, 70809 Mary Bird Perkins Cancer Center | Baton Rouge, Louisiana, United States, 70809 Woman's Hospital | Baton Rouge, Louisiana, United States, 70817 Women's Cancer Care-Covington | Covington, Louisiana, United States, 70433 Ochsner Medical Center Jefferson | New Orleans, Louisiana, United States, 70121 Eastern Maine Medical Center | Bangor, Maine, United States, 04401 Lafayette Family Cancer Center-EMMC | Brewer, Maine, United States, 04412 Maine Medical Center- Scarborough Campus | Scarborough, Maine, United States, 04074 Greater Baltimore Medical Center | Baltimore, Maryland, United States, 21204 MedStar Franklin Square Medical Center/Weinberg Cancer Institute | Baltimore, Maryland, United States, 21237 Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore, Maryland, United States, 21287 UM Upper Chesapeake Medical Center | Bel Air, Maryland, United States, 21014 National Institutes of Health Clinical Center | Bethesda, Maryland, United States, 20892 TidalHealth Richard A Henson Cancer Institute | Ocean Pines, Maryland, United States, 21811 TidalHealth Peninsula Regional | Salisbury, Maryland, United States, 21801 Brigham and Women's Hospital | Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute | Boston, Massachusetts, United States, 02215 UMass Memorial Medical Center - Memorial Division | Worcester, Massachusetts, United States, 01605 Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor, Michigan, United States, 48106 University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan, United States, 48109 Henry Ford Cancer Institute-Downriver | Brownstown, Michigan, United States, 48183 Henry Ford Macomb Hospital-Clinton Township | Clinton Township, Michigan, United States, 48038 Wayne State University/Karmanos Cancer Institute | Detroit, Michigan, United States, 48201 Henry Ford Hospital | Detroit, Michigan, United States, 48202 OSF Saint Francis Hospital and Medical Group | Escanaba, Michigan, United States, 49829 Weisberg Cancer Treatment Center | Farmington Hills, Michigan, United States, 48334 Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids, Michigan, United States, 49503 West Michigan Cancer Center | Kalamazoo, Michigan, United States, 49007 University of Michigan Health - Sparrow Lansing | Lansing, Michigan, United States, 48912 Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac, Michigan, United States, 48341 Munson Medical Center | Traverse City, Michigan, United States, 49684 Henry Ford West Bloomfield Hospital | West Bloomfield, Michigan, United States, 48322 Sanford Joe Lueken Cancer Center | Bemidji, Minnesota, United States, 56601 Fairview Ridges Hospital | Burnsville, Minnesota, United States, 55337 Mercy Hospital | Coon Rapids, Minnesota, United States, 55433 Fairview Southdale Hospital | Edina, Minnesota, United States, 55435 Mayo Clinic Health Systems-Mankato | Mankato, Minnesota, United States, 56001 Fairview Clinics and Surgery Center Maple Grove | Maple Grove, Minnesota, United States, 55369 Saint John's Hospital - Healtheast | Maplewood, Minnesota, United States, 55109 Abbott-Northwestern Hospital | Minneapolis, Minnesota, United States, 55407 University of Minnesota/Masonic Cancer Center | Minneapolis, Minnesota, United States, 55455 Mayo Clinic in Rochester | Rochester, Minnesota, United States, 55905 Park Nicollet Clinic - Saint Louis Park | Saint Louis Park, Minnesota, United States, 55416 Regions Hospital | Saint Paul, Minnesota, United States, 55101 United Hospital | Saint Paul, Minnesota, United States, 55102 Saint Francis Regional Medical Center | Shakopee, Minnesota, United States, 55379 Minnesota Oncology Hematology PA-Woodbury | Woodbury, Minnesota, United States, 55125 University of Mississippi Medical Center | Jackson, Mississippi, United States, 39216 Saint Francis Medical Center | Cape Girardeau, Missouri, United States, 63703 MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia, Missouri, United States, 65212 Mercy Hospital Joplin | Joplin, Missouri, United States, 64804 Barnes-Jewish Hospital | Saint Louis, Missouri, United States, 63110 Washington University School of Medicine | Saint Louis, Missouri, United States, 63110 Mercy Hospital Springfield | Springfield, Missouri, United States, 65804 CoxHealth South Hospital | Springfield, Missouri, United States, 65807 Billings Clinic Cancer Center | Billings, Montana, United States, 59101 Bozeman Health Deaconess Hospital | Bozeman, Montana, United States, 59715 Benefis Sletten Cancer Institute | Great Falls, Montana, United States, 59405 Nebraska Cancer Specialists/Oncology Hematology West PC | Grand Island, Nebraska, United States, 68803 CHI Health Good Samaritan | Kearney, Nebraska, United States, 68847 Nebraska Methodist Hospital | Omaha, Nebraska, United States, 68114 Alegent Health Bergan Mercy Medical Center | Omaha, Nebraska, United States, 68124 Alegent Health Lakeside Hospital | Omaha, Nebraska, United States, 68130 Women's Cancer Center of Nevada | Las Vegas, Nevada, United States, 89106 Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon, New Hampshire, United States, 03756 Dartmouth Cancer Center - Nashua | Nashua, New Hampshire, United States, 03063 Cooper Hospital University Medical Center | Camden, New Jersey, United States, 08103 Hackensack University Medical Center | Hackensack, New Jersey, United States, 07601 The Cancer Institute of New Jersey Hamilton | Hamilton, New Jersey, United States, 08690 Morristown Medical Center | Morristown, New Jersey, United States, 07960 Jersey Shore Medical Center | Neptune, New Jersey, United States, 07753 Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States, 08903 Robert Wood Johnson University Hospital Somerset | Somerville, New Jersey, United States, 08876 Overlook Hospital | Summit, New Jersey, United States, 07902 MD Anderson Cancer Center at Cooper-Voorhees | Voorhees, New Jersey, United States, 08043 Southwest Gynecologic Oncology Associates Inc | Albuquerque, New Mexico, United States, 87106 University of New Mexico Cancer Center | Albuquerque, New Mexico, United States, 87106 Memorial Medical Center - Las Cruces | Las Cruces, New Mexico, United States, 88011 Women's Cancer Care Associates LLC | Albany, New York, United States, 12208 Montefiore Medical Center-Einstein Campus | Bronx, New York, United States, 10461 State University of New York Downstate Medical Center | Brooklyn, New York, United States, 11203 Roswell Park Cancer Institute | Buffalo, New York, United States, 14263 Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York, New York, United States, 10016 University of Rochester | Rochester, New York, United States, 14642 Stony Brook University Medical Center | Stony Brook, New York, United States, 11794 State University of New York Upstate Medical University | Syracuse, New York, United States, 13210 Dickstein Cancer Treatment Center | White Plains, New York, United States, 10601 AdventHealth Infusion Center Asheville | Asheville, North Carolina, United States, 28803 UNC Lineberger Comprehensive Cancer Center | Chapel Hill, North Carolina, United States, 27599 AdventHealth Infusion Center Haywood | Clyde, North Carolina, United States, 28721 Duke University Medical Center | Durham, North Carolina, United States, 27710 Southeastern Medical Oncology Center-Goldsboro | Goldsboro, North Carolina, United States, 27534 Margaret R Pardee Memorial Hospital | Hendersonville, North Carolina, United States, 28791 AdventHealth Hendersonville | Hendersonville, North Carolina, United States, 28792 Southeastern Medical Oncology Center-Jacksonville | Jacksonville, North Carolina, United States, 28546 FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst, North Carolina, United States, 28374 Duke Raleigh Hospital | Raleigh, North Carolina, United States, 27609 Novant Health New Hanover Regional Medical Center | Wilmington, North Carolina, United States, 28401 Wake Forest University Health Sciences | Winston-Salem, North Carolina, United States, 27157 Sanford Bismarck Medical Center | Bismarck, North Dakota, United States, 58501 Sanford Broadway Medical Center | Fargo, North Dakota, United States, 58122 Sanford Roger Maris Cancer Center | Fargo, North Dakota, United States, 58122 Cleveland Clinic Akron General | Akron, Ohio, United States, 44307 Aultman Health Foundation | Canton, Ohio, United States, 44710 Miami Valley Hospital South | Centerville, Ohio, United States, 45459 University of Cincinnati Cancer Center-UC Medical Center | Cincinnati, Ohio, United States, 45219 Good Samaritan Hospital - Cincinnati | Cincinnati, Ohio, United States, 45220 TriHealth Cancer Institute-Westside | Cincinnati, Ohio, United States, 45247 MetroHealth Medical Center | Cleveland, Ohio, United States, 44109 Cleveland Clinic Cancer Center/Fairview Hospital | Cleveland, Ohio, United States, 44111 Cleveland Clinic Foundation | Cleveland, Ohio, United States, 44195 Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States, 43210 Riverside Methodist Hospital | Columbus, Ohio, United States, 43214 The Mark H Zangmeister Center | Columbus, Ohio, United States, 43219 Grandview Hospital | Dayton, Ohio, United States, 45405 Orion Cancer Care | Findlay, Ohio, United States, 45840 Hillcrest Hospital Cancer Center | Mayfield Heights, Ohio, United States, 44124 ProMedica Flower Hospital | Sylvania, Ohio, United States, 43560 ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo, Ohio, United States, 43606 University of Cincinnati Cancer Center-West Chester | West Chester, Ohio, United States, 45069 Wright-Patterson Medical Center | Wright-Patterson Air Force Base, Ohio, United States, 45433 University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma, United States, 73104 Cancer Treatment Centers of America | Tulsa, Oklahoma, United States, 74133 Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa, Oklahoma, United States, 74146 Saint Charles Health System | Bend, Oregon, United States, 97701 Legacy Mount Hood Medical Center | Gresham, Oregon, United States, 97030 Legacy Good Samaritan Hospital and Medical Center | Portland, Oregon, United States, 97210 Legacy Meridian Park Hospital | Tualatin, Oregon, United States, 97062 Jefferson Abington Hospital | Abington, Pennsylvania, United States, 19001 Saint Luke's University Hospital-Bethlehem Campus | Bethlehem, Pennsylvania, United States, 18015 Bryn Mawr Hospital | Bryn Mawr, Pennsylvania, United States, 19010 Geisinger Medical Center | Danville, Pennsylvania, United States, 17822 Ephrata Cancer Center | Ephrata, Pennsylvania, United States, 17522 Ephrata Community Hospital | Ephrata, Pennsylvania, United States, 17522 Adams Cancer Center | Gettysburg, Pennsylvania, United States, 17325 WellSpan Medical Oncology and Hematology | Hanover, Pennsylvania, United States, 17331 UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg, Pennsylvania, United States, 17109 Sechler Family Cancer Center | Lebanon, Pennsylvania, United States, 17042 Geisinger Medical Oncology-Lewisburg | Lewisburg, Pennsylvania, United States, 17837 Paoli Memorial Hospital | Paoli, Pennsylvania, United States, 19301 University of Pennsylvania/Abramson Cancer Center | Philadelphia, Pennsylvania, United States, 19104 West Penn Hospital | Pittsburgh, Pennsylvania, United States, 15224 Guthrie Medical Group PC-Robert Packer Hospital | Sayre, Pennsylvania, United States, 18840 Reading Hospital | West Reading, Pennsylvania, United States, 19611 Wexford Health and Wellness Pavilion | Wexford, Pennsylvania, United States, 15090 UPMC Susquehanna | Williamsport, Pennsylvania, United States, 17701 Asplundh Cancer Pavilion | Willow Grove, Pennsylvania, United States, 19090 Lankenau Medical Center | Wynnewood, Pennsylvania, United States, 19096 WellSpan Health-York Hospital | York, Pennsylvania, United States, 17403 Women and Infants Hospital | Providence, Rhode Island, United States, 02905 AnMed Health Cancer Center | Anderson, South Carolina, United States, 29621 Gibbs Cancer Center-Gaffney | Gaffney, South Carolina, United States, 29341 Saint Francis Hospital | Greenville, South Carolina, United States, 29601 Saint Francis Cancer Center | Greenville, South Carolina, United States, 29607 Gibbs Cancer Center-Pelham | Greer, South Carolina, United States, 29651 South Carolina Cancer Specialists PC | Hilton Head Island, South Carolina, United States, 29926-3827 Spartanburg Medical Center | Spartanburg, South Carolina, United States, 29303 MGC Hematology Oncology-Union | Union, South Carolina, United States, 29379 Rapid City Regional Hospital | Rapid City, South Dakota, United States, 57701 Sanford Cancer Center Oncology Clinic | Sioux Falls, South Dakota, United States, 57104 Avera Cancer Institute | Sioux Falls, South Dakota, United States, 57105 Sanford USD Medical Center - Sioux Falls | Sioux Falls, South Dakota, United States, 57117-5134 Ballad Health Cancer Care - Kingsport | Kingsport, Tennessee, United States, 37660 Wellmont Holston Valley Hospital and Medical Center | Kingsport, Tennessee, United States, 37660 Thompson Cancer Survival Center | Knoxville, Tennessee, United States, 37916 Thompson Cancer Survival Center - West | Knoxville, Tennessee, United States, 37932 Vanderbilt University/Ingram Cancer Center | Nashville, Tennessee, United States, 37232 Parkland Memorial Hospital | Dallas, Texas, United States, 75235 UT Southwestern/Simmons Cancer Center-Dallas | Dallas, Texas, United States, 75390 Houston Methodist Hospital | Houston, Texas, United States, 77030 Methodist Willowbrook Hospital | Houston, Texas, United States, 77070 Houston Methodist Sugar Land Hospital | Sugar Land, Texas, United States, 77479 Intermountain Medical Center | Murray, Utah, United States, 84107 Saint George Regional Medical Center | Saint George, Utah, United States, 84770 Utah Cancer Specialists-Salt Lake City | Salt Lake City, Utah, United States, 84106 Huntsman Cancer Institute/University of Utah | Salt Lake City, Utah, United States, 84112 South Jordan Health Center | South Jordan, Utah, United States, 84009 Central Vermont Medical Center/National Life Cancer Treatment | Berlin, Vermont, United States, 05602 University of Vermont Medical Center | Burlington, Vermont, United States, 05401 University of Vermont and State Agricultural College | Burlington, Vermont, United States, 05405 University of Virginia Cancer Center | Charlottesville, Virginia, United States, 22908 VCU Massey Cancer Center at Stony Point | Richmond, Virginia, United States, 23235 Virginia Commonwealth University/Massey Cancer Center | Richmond, Virginia, United States, 23298 PeaceHealth Saint Joseph Medical Center | Bellingham, Washington, United States, 98225 Swedish Cancer Institute-Edmonds | Edmonds, Washington, United States, 98026 Kadlec Clinic Hematology and Oncology | Kennewick, Washington, United States, 99336 Skagit Regional Health Cancer Care Center | Mount Vernon, Washington, United States, 98274 Skagit Valley Hospital | Mount Vernon, Washington, United States, 98274 Pacific Gynecology Specialists | Seattle, Washington, United States, 98104 FHCC South Lake Union | Seattle, Washington, United States, 98109 Fred Hutchinson Cancer Center | Seattle, Washington, United States, 98109 Swedish Medical Center-First Hill | Seattle, Washington, United States, 98122 University of Washington Medical Center - Northwest | Seattle, Washington, United States, 98133 Women's Cancer Center of Seattle | Seattle, Washington, United States, 98133 University of Washington Medical Center - Montlake | Seattle, Washington, United States, 98195 Legacy Salmon Creek Hospital | Vancouver, Washington, United States, 98686 Wenatchee Valley Hospital and Clinics | Wenatchee, Washington, United States, 98801 West Virginia University Charleston Division | Charleston, West Virginia, United States, 25304 Edwards Comprehensive Cancer Center | Huntington, West Virginia, United States, 25701 Monongalia Hospital | Morgantown, West Virginia, United States, 26505 West Virginia University Healthcare | Morgantown, West Virginia, United States, 26506 Ascension Saint Elizabeth Hospital | Appleton, Wisconsin, United States, 54915 Aurora Cancer Care-Southern Lakes VLCC | Burlington, Wisconsin, United States, 53105 Marshfield Clinic-Chippewa Center | Chippewa Falls, Wisconsin, United States, 54729 Marshfield Clinic Cancer Center at Sacred Heart | Eau Claire, Wisconsin, United States, 54701 Aurora Health Center-Fond du Lac | Fond Du Lac, Wisconsin, United States, 54937 Aurora Health Care Germantown Health Center | Germantown, Wisconsin, United States, 53022 Aurora Cancer Care-Grafton | Grafton, Wisconsin, United States, 53024 Saint Vincent Hospital Cancer Center Green Bay | Green Bay, Wisconsin, United States, 54301 Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay, Wisconsin, United States, 54303 Aurora BayCare Medical Center | Green Bay, Wisconsin, United States, 54311 Aurora Cancer Care-Kenosha South | Kenosha, Wisconsin, United States, 53142 Gundersen Lutheran Medical Center | La Crosse, Wisconsin, United States, 54601 Marshfield Medical Center - Ladysmith | Ladysmith, Wisconsin, United States, 54848 University of Wisconsin Carbone Cancer Center - University Hospital | Madison, Wisconsin, United States, 53792 Aurora Bay Area Medical Group-Marinette | Marinette, Wisconsin, United States, 54143 Saint Vincent Hospital Cancer Center at Marinette | Marinette, Wisconsin, United States, 54143 Marshfield Medical Center-Marshfield | Marshfield, Wisconsin, United States, 54449 Ascension Columbia Saint Mary's Hospital Ozaukee | Mequon, Wisconsin, United States, 53097 Aurora Cancer Care-Milwaukee | Milwaukee, Wisconsin, United States, 53209 Ascension Columbia Saint Mary's Hospital - Milwaukee | Milwaukee, Wisconsin, United States, 53211 Aurora Saint Luke's Medical Center | Milwaukee, Wisconsin, United States, 53215 Medical College of Wisconsin | Milwaukee, Wisconsin, United States, 53226 Aurora Sinai Medical Center | Milwaukee, Wisconsin, United States, 53233 Marshfield Clinic-Minocqua Center | Minocqua, Wisconsin, United States, 54548 ProHealth D N Greenwald Center | Mukwonago, Wisconsin, United States, 53149 ProHealth Oconomowoc Memorial Hospital | Oconomowoc, Wisconsin, United States, 53066 Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls, Wisconsin, United States, 54154 Ascension Mercy Hospital | Oshkosh, Wisconsin, United States, 54904 Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh, Wisconsin, United States, 54904 Aurora Cancer Care-Racine | Racine, Wisconsin, United States, 53406 Marshfield Medical Center-Rice Lake | Rice Lake, Wisconsin, United States, 54868 Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan, Wisconsin, United States, 53081 Ascension Saint Michael's Hospital | Stevens Point, Wisconsin, United States, 54481 Marshfield Medical Center-River Region at Stevens Point | Stevens Point, Wisconsin, United States, 54482 Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay, Wisconsin, United States, 54235-1495 Aurora Medical Center in Summit | Summit, Wisconsin, United States, 53066 Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers, Wisconsin, United States, 54241 ProHealth Waukesha Memorial Hospital | Waukesha, Wisconsin, United States, 53188 UW Cancer Center at ProHealth Care | Waukesha, Wisconsin, United States, 53188 Marshfield Clinic-Wausau Center | Wausau, Wisconsin, United States, 54401 Aurora Cancer Care-Milwaukee West | Wauwatosa, Wisconsin, United States, 53226 Aurora West Allis Medical Center | West Allis, Wisconsin, United States, 53227 Marshfield Medical Center - Weston | Weston, Wisconsin, United States, 54476 Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids, Wisconsin, United States, 54494 Tom Baker Cancer Centre | Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute | Edmonton, Alberta, Canada, T6G 1Z2 Royal Victoria Regional Health Centre | Barrie, Ontario, Canada, L4M 6M2 Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton, Ontario, Canada, L8V 5C2 Kingston Health Sciences Centre | Kingston, Ontario, Canada, K7L 2V7 London Regional Cancer Program | London, Ontario, Canada, N6A 4L6 Algoma District Cancer Program Sault Area Hospital | Sault Ste Marie, Ontario, Canada, P6B 0A8 Odette Cancer Centre- Sunnybrook Health Sciences Centre | Toronto, Ontario, Canada, M4N 3M5 University Health Network-Princess Margaret Hospital | Toronto, Ontario, Canada, M5G 2M9 CIUSSSEMTL-Hopital Maisonneuve-Rosemont | Montreal, Quebec, Canada, H1T 2M4 CHUM - Hopital Notre-Dame | Montreal, Quebec, Canada, H2L 4M1 CHUM - Centre Hospitalier de l'Universite de Montreal | Montreal, Quebec, Canada, H2X 3E4 Jewish General Hospital | Montreal, Quebec, Canada, H3T 1E2 CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) | Quebec City, Quebec, Canada, G1R 2J6 Ehime University Hospital | Toon, Ehime, Japan, 791-0295 Hokkaido University Hospital | Sapporo, Hokkaido, Japan, 060-8648 Kagoshima City Hospital | Kagoshima City, Kagoshima, Japan, 890-8760 The Cancer Institute Hospital Of JFCR | Koto-ku, Tokyo, Japan, 135-8550 Kindai University | Osaka, Japan, 589 8511 Saitama Medical University International Medical Center | Saitama, Japan, 350-1298 National Cancer Center Hospital | Tokyo, Japan, 104 0045 Keimyung University-Dongsan Medical Center | Dalseo-gu, Daegu, Korea, Republic of, 42601 Seoul National University Bundang Hospital | Seongnam City, Kyeonggi-do, Korea, Republic of, 463-707 Gachon University Gil Hospital | Incheon, Korea, Republic of, 405-760 Asan Medical Center | Seoul, Korea, Republic of, 05505 Gangnam Severance Hospital | Seoul, Korea, Republic of, 06273 Kyung Hee University Hospital at Gangdong | Seoul, Korea, Republic of, 134-727 Korea Cancer Center Hospital | Seoul, Korea, Republic of, 139-706 Centro Comprensivo de Cancer de UPR | San Juan, Puerto Rico, 00927
Investigators	Principal Investigator: Jung-min Lee, NRG Oncology

More Information

Additional Relevant MeSH Terms

• Carcinoma
• Adenocarcinoma
• Carcinoma, Transitional Cell
• Cystadenocarcinoma, Serous
• Carcinoma, Endometrioid
• Adenocarcinoma, Clear Cell
• Recurrence
• Neoplasms, Glandular and Epithelial
• Neoplasms by Histologic Type
• Neoplasms
• Disease Attributes
• Pathologic Processes
• Ovarian Neoplasms
• Neoplasms by Site
• Ovarian Diseases
• Adnexal Diseases
• Genital Diseases, Female
• Female Urogenital Diseases
• Female Urogenital Diseases and Pregnancy Complications
• Urogenital Diseases
• Genital Neoplasms, Female
• Urogenital Neoplasms
• Genital Diseases
• Endocrine System Diseases
• Gonadal Disorders
• Cystadenocarcinoma
• Neoplasms, Cystic, Mucinous, and Serous
• Endometrial Neoplasms
• Uterine Neoplasms